243 related articles for article (PubMed ID: 22388712)
1. The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase.
Andersen MH
Cancer Immunol Immunother; 2012 Aug; 61(8):1289-97. PubMed ID: 22388712
[TBL] [Abstract][Full Text] [Related]
2. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.
Sørensen RB; Berge-Hansen L; Junker N; Hansen CA; Hadrup SR; Schumacher TN; Svane IM; Becker JC; thor Straten P; Andersen MH
PLoS One; 2009 Sep; 4(9):e6910. PubMed ID: 19738905
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.
Sørensen RB; Hadrup SR; Svane IM; Hjortsø MC; Thor Straten P; Andersen MH
Blood; 2011 Feb; 117(7):2200-10. PubMed ID: 21079151
[TBL] [Abstract][Full Text] [Related]
4. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase.
Munir S; Larsen SK; Iversen TZ; Donia M; Klausen TW; Svane IM; Straten PT; Andersen MH
PLoS One; 2012; 7(4):e34568. PubMed ID: 22539948
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
6. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Zahm CD; Johnson LE; McNeel DG
Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
8. IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
Munn DH; Mellor AL
Trends Immunol; 2016 Mar; 37(3):193-207. PubMed ID: 26839260
[TBL] [Abstract][Full Text] [Related]
9. Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.
Johnson TS; Mcgaha T; Munn DH
Adv Exp Med Biol; 2017; 1036():91-104. PubMed ID: 29275467
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
Soliman H; Mediavilla-Varela M; Antonia S
Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
14. Blockage of indoleamine 2,3-dioxygenase regulates Japanese encephalitis via enhancement of type I/II IFN innate and adaptive T-cell responses.
Kim SB; Choi JY; Uyangaa E; Patil AM; Hossain FM; Hur J; Park SY; Lee JH; Kim K; Eo SK
J Neuroinflammation; 2016 Apr; 13(1):79. PubMed ID: 27090635
[TBL] [Abstract][Full Text] [Related]
15. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.
Sørensen RB; Køllgaard T; Andersen RS; van den Berg JH; Svane IM; Straten Pt; Andersen MH
Cancer Res; 2011 Mar; 71(6):2038-44. PubMed ID: 21406395
[TBL] [Abstract][Full Text] [Related]
17. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.
Noh KT; Son KH; Jung ID; Kang TH; Choi CH; Park YM
J Biol Chem; 2015 May; 290(19):12394-402. PubMed ID: 25814664
[TBL] [Abstract][Full Text] [Related]
18. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
19. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity.
Gu T; Rowswell-Turner RB; Kilinc MO; Egilmez NK
Cancer Res; 2010 Jan; 70(1):129-38. PubMed ID: 20028855
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy.
Yentz S; Smith D
BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
